RAS is the most widely mutated oncogene in cancers, occurring in nearly 30% of human tumors. The RAS family includes three subtypes: KRAS, HRAS, and NRAS, with KRAS mutations accounting for approximately 85% of RAS family mutations. KRAS functions as a molecular switch, transmitting signals from membrane-bound receptors to regulate cellular processes by transitioning between GTP-bound active and GDP-bound inactive states. KRAS mutations are primarily concentrated at four hotspot codons (12, 13, 61, and 146), with codon 12 mutations being the most frequent. Among these, the G12D mutation is the most common, followed by G12V, G12C, and others.
The KRAS G12D mutation holds significant clinical importance across various cancers. In pancreatic cancer, its incidence is approximately 90% in the U.S. and 87% in China; in colorectal cancer, about 45% in the U.S. and 49% in China; and in the adenocarcinoma subtype of non-small cell lung cancer (NSCLC), around 35% in the U.S. and 13% in China. The distribution of KRAS mutations varies by tumor type, with G12C mutations occurring in approximately 13.6% of lung adenocarcinomas, while G12D and G12V are the two most prevalent mutation types in colorectal and pancreatic cancers. The G12D mutation reduces GTP hydrolysis rates by 2-3 times, causing KRAS protein to remain constitutively active, posing greater challenges for drug development targeting this mutation.
KRAS has been dubbed the "Death Star" protein. Since its discovery in 1982, it was long considered "undruggable." The main reasons include: RAS binds GTP with picomolar affinity, while intracellular GTP concentrations reach 0.5 mmol·L⁻¹, making competitive inhibitor development extremely difficult; the KRAS protein surface is smooth, with a nearly spherical spatial structure lacking small-molecule binding pockets; and the D domains across RAS subtypes are highly similar, resulting in poor targeting selectivity.
The discovery of KRAS's switch pocket II and the unique property of the newly introduced cysteine at the KRAS G12C mutation site—which readily forms covalent bonds—enabled the design of irreversible covalent small-molecule inhibitors targeting cysteine residues at codon 12. This breakthrough proved that KRAS mutations are not "undruggable." However, the KRAS G12D mutation involves substitution of glycine at codon 12 with aspartate, which terminates in a carboxyl group. This mutant subtype lacks amino acid residues near switch pocket II for covalent binding, rendering the covalent strategy used for G12C inhibitors inapplicable. Thus, developing high-affinity, highly selective inhibitors for the G12D mutation requires entirely new approaches.
Currently, the most advanced global development stage for KRAS G12D-targeted inhibitors is Phase II clinical trials. Drug modalities targeting this mutation include small-molecule chemicals, PROTACs, TCR cell therapies, and siRNAs, with indications covering KRAS G12D-mutant solid tumors, including NSCLC, colorectal cancer, pancreatic cancer, endometrial cancer, and others.
In the PROTAC technology field, the TR-FRET KRAS [G12D]/CRBN PROTAC Assay Kit serves as a critical research tool. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) principles, this kit detects interactions between KRAS G12D mutant protein and CRBN E3 ligase, evaluating PROTAC molecule-induced target protein degradation efficiency. This standardized assay system enables high-throughput screening of potential KRAS G12D degraders, accelerating candidate compound optimization.
Reliable research tools are essential for assessing compound activity in KRAS G12D-targeted drug development. The TR-FRET KRAS [G12D]/CRBN PROTAC Assay Kit provides a standardized platform for PROTAC drug screening. This kit quantitatively measures PROTAC molecules' ability to simultaneously bind KRAS G12D protein and CRBN, reflecting ternary complex formation efficiency and predicting intracellular degradation activity.
Compared to traditional methods, this kit offers advantages such as homogeneous assay format, high sensitivity, and low sample consumption, making it suitable for large-scale compound screening and structure-activity relationship studies. Researchers can systematically evaluate PROTAC molecules' degradation selectivity for KRAS G12D mutant protein, providing experimental evidence for developing highly specific degraders with minimal off-target effects. Additionally, the kit assesses PROTACs' cooperative binding effects, aiding in understanding degrader structure-activity relationships and mechanisms of action.
KRAS G12D-targeted therapy still faces numerous challenges, but novel drug modalities like PROTAC technology offer new avenues to overcome the "undruggable" barrier. Although binding pockets exist in the GDP-bound state, the G12D mutation's reduced GTP hydrolysis rates and enhanced constitutive activation make pharmacological strategies targeting the inactive state less effective than those for G12C. With widespread adoption of standardized tools like the TR-FRET KRAS [G12D]/CRBN PROTAC Assay Kit, discovery efficiency for KRAS G12D-selective degraders will significantly improve. Future integration of structural biology and computational chemistry may yield highly effective therapeutic strategies for KRAS G12D mutations, opening new directions for related research fields.
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "UniOne® TR-FRET Human KRAS[G12D]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog No.: UA086002), a high-performance analytical platform specifically designed for studying PROTAC molecules that induce interactions between KRAS G12D mutant protein and CRBN (Cereblon) E3 ubiquitin ligase. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit supports evaluation of PROTAC-mediated ternary complex formation between KRAS G12D and CRBN under GDP- or GTP-loaded states, providing a stable and reliable standardized solution for targeted protein degradation (PROTAC) technology development, anticancer drug screening, and mutation-specific degrader research.
| Core Product Advantages | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Intact Bioactivity | The kit's core components feature rigorously quality-controlled, high-purity human KRAS G12D mutant protein (compatible with GDP/GTP loading states) and CRBN-DDB1 complex with preserved biological activity. The KRAS G12D protein maintains correct native conformation and nucleotide-binding states, authentically simulating physiological PROTAC-mediated KRAS G12D-CRBN ternary complex formation to ensure accurate, reproducible, and functionally relevant data. |
| Exceptional Batch-to-Batch Consistency and Stability | Leveraging internationally advanced protein expression platforms and highly standardized production processes combined with stringent release QC systems, the product delivers outstanding long-term stability and excellent batch-to-batch consistency, providing solid quality assurance for continuous PROTAC drug screening and mechanistic research. |
| Ready-to-Use Flexible Platform | This homogeneous TR-FRET-based kit adopts a simple "add-incubate-read" workflow without washing steps. Its optimized formulation supports automated 96/384-well plate platforms, enabling flexible applications in high-throughput screening of KRAS G12D-targeting PROTACs, nucleotide state-dependent degrader evaluation, ternary complex formation assays, and competitive binding studies. |
| Comprehensive Solutions and Expert Support | We provide fully validated standard protocols, representative dose-response curves, and detailed data interpretation guides to facilitate rapid establishment of robust, reproducible workflows. Nanjing UA-Bio's technical team offers end-to-end professional consultation and support for experimental design, optimization, and data analysis. |
Nanjing UA-Bio Technology Co., Ltd. remains committed to delivering cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical specifications, validation data, or application inquiries regarding the "UniOne® TR-FRET Human KRAS[G12D]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog No.: UA086002), please feel free to contact us.
